ACST News and Press, Acasti Pharma Inc. From 11/14/22

Acasti Pharma Inc. (ACST) Q2 2023 Earnings Conference Call November 14, 2022 01:00 PM ET Company Participants Robert Blum - Lytham Partners, IR Jan D'Alvise - President & CEO Brian Ford - CFO Prashant Kohli - Chief Commercial Officer Conference Call...

Acasti Pharma press release ( NASDAQ: ACST ): Q3 GAAP EPS of -$0.11. The Company finished the second fiscal quarter ended September 30, 2022, with $34.9 million in cash, cash equivalents and short-term investments. For further details see: Acasti Pharma GAAP EPS ...

Company to Host Conference Call Today at 1:00pm ET LAVAL, Québec, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical s...

LAVAL, Québec, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today a...

LAVAL, Quebec, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, today announ...

Acasti Pharma (NASDAQ: ACST) (TSX.V: ACST) is a specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases. Acasti’s novel drug candidates have the potential to improve the performance of currently marketed drugs by achieving fas...

Canadian biopharma ( NASDAQ: ACST ) gained in the morning hours Friday after the company announced that a U.S. court dismissed a shareholder lawsuit related to its 2021 acquisition of privately held Grace Therapeutics. The company and several executives have faced four sto...

LAVAL, Québec, Sept. 30, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan diseases, announ...

LAVAL, Québec, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“ Acasti ” or the “ Company ”) (NASDAQ: ACST and TSX-V: ACST), a late-stage, specialty pharma company advancing three clinical stage drug candidates addressing rare and orphan dise...

Phoenix, Arizona--(Newsfile Corp. - September 21, 2022) - The Stock Day Podcast welcomed Acasti Pharma Inc. (NASDAQ: ACST) ("the Company"), a specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. CEO of the Company, Jan D'Alvise, join...